ClinicalTrials.gg
CompletedNCT01225562PEGASUSUpdated Jan 25, 2016Results posted

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

A Phase 3 interventional study of Ticagrelor 90 mg and Ticagrelor 60 mg in Myocardial Infarction, Cardiovascular Death and Atherothrombosis, sponsored by AstraZeneca. Completed at 847 sites in 31 countries. Open to participants aged 50 Years to 130 Years. Per ClinicalTrials.gov, last updated 2016-01-25.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21,379
Allocation
Randomized
Ages
50 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing ticagrelor in Myocardial Infarction — 3 open to participants now, 3 under way, 1 of them phase 3. Ticagrelor · Myocardial Infarction.

Enrollment
Largest of 36
21,379 · median 132
Started
2010
the only one that year
Phase 3
11 of 36
1 open now
Registered
4th of 36
by date
Lead sponsor
6 of 36
AstraZeneca

Among the 36 studies testing ticagrelor in Myocardial Infarction, this one has the largest enrollment, is the only one that started in 2010, is one of 11 in phase 3, and was the 4th registered.

Myocardial Infarction

2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

3 of the 36 studies testing ticagrelor in Myocardial Infarction are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 50 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing ticagrelor in Myocardial Infarction, or all of them as a file.
02

Study summary

This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).

03

Conditions studied

  • Myocardial Infarction
  • Cardiovascular Death
  • Atherothrombosis
  • Stroke

Keywords

  • Heart attack
  • Heart Disease
  • Acute coronary syndrome
  • ACS
  • Cardiovascular Disease
04

Who can participate

Ages eligible
50 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Person who had a heart attack within 1 - 3 years ago and at least one additional risk factor: Age ≥ 65 years old, Diabetes requiring medication, Documented history of 2nd prior MI (>1 year ago). Angiographic evidence of multivessel CAD, and / or Chronic, non-end stage renal dysfunction.
  • Females of must have a negative pregnancy test at enrollment
  • Persons who are currently taking aspirin between 75 and 150 mg once daily

Exclusion criteria

Exclusion Criteria:

  • Persons who are being treated with agents inhibiting blood clotting if the agent cannot be stopped at study start
  • Persons who have planned coronary, cerebrovascular, or peripheral arterial Revascularization (invasive surgery) at study start
  • Persons with known bleeding disorders
  • Persons who need chronic oral anticoagulant therapy or chronic low-molecular-weight heparin
  • Persons with a history of ischemic stroke
  • Persons with a history of intracranial bleeding at any time, a tumor or blood vessel abnormality in the brain and/or spinal cord at any time, a history of surgery involving the brain or spinal cord within the last 5 years, or a history of bleeding from the gastrointestinal tract (eg, esophagus, stomach, colon, rectum) within the last 6 months or a major surgery within the last 30 days.
  • Persons considered to be at risk of bradycardic events unless already treated with a permanent pacemaker
  • Persons who have had open heart surgery within the past 5 years, unless the person had a heart attack after the surgery
  • Persons with known severe liver disease
  • Persons with kidney failure requiring dialysis
  • Persons with \< 1 year
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
21,379 participants (actual)

Study arms

  • Experimental
    1

    Oral Treatment

    Drug: Ticagrelor 90 mg

  • Experimental
    2

    Oral Treatment

    Drug: Ticagrelor 60 mg

  • Placebo comparator
    3

    Oral Treatment

    Drug: Ticagrelor Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization

    Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization

    Time frame: Randomization up to 47 months

  2. Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients

    A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of \>= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug

    Time frame: First dosing up to 48 months

Secondary outcomes

  1. Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization

    Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization

    Time frame: Randomization up to 47 months

  2. Kaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization

    Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization

    Time frame: Randomization up to 47 months

07

Results

Posted Dec 9, 2015

Participant flow

Participant flow — Overall Study
MilestoneTicagrelor 90 mgTicagrelor 60 mgPlacebo
Started705070457067
Completed699569897014
Not completed555653
Withdrew: Withdrawal by subject525052
Withdrew: Lost to follow-up361

Outcome measures

PrimaryKaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization

Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization

Time frame:
Randomization up to 47 months
Reported as:
Number · Percentage of Patients
Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization
Percentage of PatientsTicagrelor 90 mgTicagrelor 60 mgPlacebo
Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization7.87.89.0
Statistical analysis
  • Ticagrelor 90 mg vs Placebo · Regression, Cox · p = 0.0080 · Hazard ratio (hr): 0.85 · 95% CI 0.75 to 0.96The hazard ratio shows ticagrelor 90 mg hazard / placebo hazard
  • Ticagrelor 60 mg vs Placebo · Regression, Cox · p = 0.0043 · Hazard ratio (hr): 0.84 · 95% CI 0.74 to 0.95The hazard ratio shows ticagrelor 60 mg hazard / placebo hazard
SecondaryKaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization

Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization

Time frame:
Randomization up to 47 months
Reported as:
Number · Percentage of Patients
Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization
Percentage of PatientsTicagrelor 90 mgTicagrelor 60 mgPlacebo
Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization2.92.93.4
Statistical analysis
  • Ticagrelor 90 mg vs Placebo · Regression, Cox · p = 0.1547 · Hazard ratio (hr): 0.87 · 95% CI 0.71 to 1.06The hazard ratio shows ticagrelor 90 mg hazard / placebo hazard
  • Ticagrelor 60 mg vs Placebo · Regression, Cox · p = 0.0676 · Hazard ratio (hr): 0.83 · 95% CI 0.68 to 1.01The hazard ratio shows ticagrelor 60 mg hazard / placebo hazard
SecondaryKaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization

Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization

Time frame:
Randomization up to 47 months
Reported as:
Number · Percentage of Patients
Kaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization
Percentage of PatientsTicagrelor 90 mgTicagrelor 60 mgPlacebo
Kaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization5.14.75.2
Statistical analysis
  • Ticagrelor 90 mg vs Placebo · Regression, Cox · p = 0.9851 · Hazard ratio (hr): 1.00 · 95% CI 0.86 to 1.16The hazard ratio shows ticagrelor 90 mg hazard / placebo hazard
  • Ticagrelor 60 mg vs Placebo · Regression, Cox · p = 0.1350 · Hazard ratio (hr): 0.89 · 95% CI 0.76 to 1.04The hazard ratio shows ticagrelor 60 mg hazard / placebo hazard
PrimaryKaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients

A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of \>= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug

Time frame:
First dosing up to 48 months
Reported as:
Number · Percentage of Patients
Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients
Percentage of PatientsTicagrelor 90 mgTicagrelor 60 mgPlacebo
Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients2.62.31.1
Statistical analysis
  • Ticagrelor 90 mg vs Placebo · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 2.69 · 95% CI 1.96 to 3.70The hazard ratio shows ticagrelor 90 mg hazard / placebo hazard
  • Ticagrelor 60 mg vs Placebo · Regression, Cox · p = <0.0001 · Hazard ratio (hr): 2.32 · 95% CI 1.68 to 3.21The hazard ratio shows ticagrelor 60 mg hazard / placebo hazard

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1,757/6,996 (25.1%)945/6,996 (13.5%)
Ticagrelor 60mg bd—1,853/6,958 (26.6%)1,992/6,958 (28.6%)
Ticagrelor 90mg bd—1,918/6,988 (27.4%)2,245/6,988 (32.1%)
Most frequent serious events
Showing 10 of 1,428
Most frequent serious events
EventPlaceboTicagrelor 60mg bdTicagrelor 90mg bd
Non-cardiac chest painGeneral disorders109/6996113/6958115/6988
Atrial fibrillationCardiac disorders67/699694/695874/6988
PneumoniaInfections and infestations76/699669/695877/6988
Cardiac failure congestiveCardiac disorders51/699653/695870/6988
OsteoarthritisMusculoskeletal and connective tissue disorders59/699654/695854/6988
Cardiac failureCardiac disorders58/699653/695854/6988
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders45/699639/695854/6988
Angina pectorisCardiac disorders51/699645/695851/6988
DeathGeneral disorders42/699634/695842/6988
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)37/699629/695838/6988
Most frequent other events
Most frequent other events
EventPlaceboTicagrelor 60mg bdTicagrelor 90mg bd
DyspnoeaRespiratory, thoracic and mediastinal disorders329/6996876/69581091/6988
EpistaxisRespiratory, thoracic and mediastinal disorders165/6996420/6958505/6988
Increased tendency to bruiseBlood and lymphatic system disorders65/6996419/6958464/6988
ContusionInjury, poisoning and procedural complications111/6996353/6958385/6988
NasopharyngitisInfections and infestations377/6996364/6958368/6988

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ticagrelor 90 mgTicagrelor 60 mgPlaceboTotal
Mean65.4 ± 8.465.2 ± 8.465.4 ± 8.365.3 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Ticagrelor 90 mgTicagrelor 60 mgPlaceboTotal
Female1682166117175060
Male53685384535016102
08

Study locations

847 sites
  • Research Site
    Alexander City, Alabama, United States
  • Research Site
    Athens, Alabama, United States
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Huntsville, Alabama, United States
  • Research Site
    Mobile, Alabama, United States
  • Research Site
    Sheffield, Alabama, United States
  • Research Site
    Glendale, Arizona, United States
  • Research Site
    Phoenix, Arizona, United States
  • Research Site
    Jonesboro, Arkansas, United States
  • Research Site
    Little Rock, Arkansas, United States
  • Research Site
    Alhambra, California, United States
  • Research Site
    Anaheim, California, United States
  • Research Site
    Bakersfield, California, United States
  • Research Site
    Fountain Valley, California, United States
  • Research Site
    La Mesa, California, United States
  • Research Site
    Larkspur, California, United States
  • Research Site
    Lomita, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Modesto, California, United States
  • Research Site
    Newport Beach, California, United States
  • Research Site
    Oakland, California, United States
  • Research Site
    Oceanside, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    San Marino, California, United States
  • Research Site
    Santa Rosa, California, United States
  • Research Site
    Ventura, California, United States
  • Research Site
    Westlake Village, California, United States
  • Research Site
    Aurora, Colorado, United States
  • Research Site
    Colorado Springs, Colorado, United States
  • Research Site
    Littleton, Colorado, United States
  • Research Site
    Loveland, Colorado, United States
  • Research Site
    Hartford, Connecticut, United States
  • Research Site
    Stamford, Connecticut, United States
  • Research Site
    Newark, Delaware, United States
  • Research Site
    Washington, District of Columbia, United States
  • Research Site
    Boca Raton, Florida, United States
  • Research Site
    Clearwater, Florida, United States
  • Research Site
    Coral Springs, Florida, United States
  • Research Site
    Crystal River, Florida, United States
  • Research Site
    Davie, Florida, United States
  • Research Site
    Daytona Beach, Florida, United States
  • Research Site
    Daytona, Florida, United States
  • Research Site
    Ft Lauderdale, Florida, United States
  • Research Site
    Gainesville, Florida, United States
  • Research Site
    Hialeah, Florida, United States
  • Research Site
    Hollywood, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Jupiter, Florida, United States
  • Research Site
    Largo, Florida, United States
  • Research Site
    Leesburg, Florida, United States
  • Research Site
    Miami Beach, Florida, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    Naples, Florida, United States
  • Research Site
    Ocala, Florida, United States
  • Research Site
    Orlando, Florida, United States
  • Research Site
    Pannama City, Florida, United States
  • Research Site
    Pensacola, Florida, United States
  • Research Site
    Port Charlotte, Florida, United States
  • Research Site
    Safety Harbor, Florida, United States
  • Research Site
    Sarasota, Florida, United States
  • Research Site
    South Miami, Florida, United States
  • Research Site
    St Petersburg, Florida, United States
  • Research Site
    Tallahassee, Florida, United States
  • Research Site
    The Villages, Florida, United States
  • Research Site
    Wellington, Florida, United States
  • Research Site
    West Palm Beach, Florida, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Augusta, Georgia, United States
  • Research Site
    Cumming, Georgia, United States
  • Research Site
    Honolulu, Hawaii, United States
  • Research Site
    Boise, Idaho, United States
  • Research Site
    Aurora, Illinois, United States
  • Research Site
    Bannockburn, Illinois, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Melrose Park, Illinois, United States
  • Research Site
    Normal, Illinois, United States
  • Research Site
    Rock Island, Illinois, United States
  • Research Site
    Avon, Indiana, United States
  • Research Site
    Elkhart, Indiana, United States
  • Research Site
    Fort Wayne, Indiana, United States
  • Research Site
    Franklin, Indiana, United States
  • Research Site
    Indianapolis, Indiana, United States
  • Research Site
    Muncie, Indiana, United States
  • Research Site
    Munster, Indiana, United States
  • Research Site
    Iowa City, Iowa, United States
  • Research Site
    Hutchinson, Kansas, United States
  • Research Site
    Crestview Hills, Kentucky, United States
  • Research Site
    Lexington, Kentucky, United States
  • Research Site
    Louisville, Kentucky, United States
  • Research Site
    Alexandria, Louisiana, United States
  • Research Site
    Covington, Louisiana, United States
  • Research Site
    Minden, Louisiana, United States
  • Research Site
    New Iberia, Louisiana, United States
  • Research Site
    Opelousas, Louisiana, United States
  • Research Site
    Shreveport, Louisiana, United States
  • Research Site
    Slidell, Louisiana, United States
  • Research Site
    Auburn, Maine, United States
  • Research Site
    Bangor, Maine, United States
  • Research Site
    Biddeford, Maine, United States
  • Research Site
    S Portland, Maine, United States

Showing the first 100 of 847 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14. PubMed 25773268 ↗
  • Bonaca MP, Im K, Magnani G, Bansilal S, Dellborg M, Storey RF, Bhatt DL, Steg PG, Cohen M, Johanson P, Braunwald E, Sabatine MS. Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54. Eur Heart J. 2022 Dec 21;43(48):5037-5044. doi: 10.1093/eurheartj/ehac402. PubMed 36367709 ↗
  • Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4. PubMed 35224730 ↗
  • Bergmark BA, Bhatt DL, Steg PG, Budaj A, Storey RF, Gurmu Y, Kuder JF, Im K, Magnani G, Oude Ophuis T, Hamm C, Spinar J, Kiss RG, Van de Werf FJ, Montalescot G, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2021 Sep 7;10(17):e020446. doi: 10.1161/JAHA.120.020446. Epub 2021 Aug 21. PubMed 34423649 ↗
  • Magnani G, Ardissino D, Im K, Budaj A, Storey RF, Steg PG, Bhatt DL, Cohen M, Oude Ophius T, Goudev A, Parkhomenko A, Kamensky G, Angiolillo DJ, Lopez-Sendon J, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. J Am Heart Assoc. 2021 Feb 16;10(4):e017008. doi: 10.1161/JAHA.120.017008. Epub 2021 Feb 9. PubMed 33559485 ↗
  • Furtado RHM, Venkateswaran RV, Nicolau JC, Gurmu Y, Bhatt DL, Storey RF, Steg PG, Magnani G, Goto S, Dellborg M, Kamensky G, Isaza D, Aylward P, Johanson P, Bonaca MP. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2020 May 18;9(10):e015785. doi: 10.1161/JAHA.119.015785. Epub 2020 May 15. PubMed 32410485 ↗
  • Gencer B, Li XS, Gurmu Y, Bonaca MP, Morrow DA, Cohen M, Bhatt DL, Steg PG, Storey RF, Johanson P, Wang Z, Hazen SL, Sabatine MS. Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2020 May 18;9(10):e015331. doi: 10.1161/JAHA.119.015331. Epub 2020 May 5. PubMed 32366163 ↗
  • Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F, Corbalan R, Kiss RG, Abola MT, Johanson P, Jensen EC, Braunwald E, Sabatine MS, Bonaca MP. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. Eur Heart J. 2020 May 1;41(17):1625-1632. doi: 10.1093/eurheartj/ehz821. PubMed 31811715 ↗
  • Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Oude Ophuis T, Budaj A, Hamm C, Spinar J, Kiss RG, Lopez-Sendon J, Kamensky G, Van de Werf F, Ardissino D, Kontny F, Montalescot G, Johanson P, Bengtsson O, Himmelmann A, Braunwald E, Sabatine MS. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):200-206. doi: 10.1093/ehjcvp/pvz020. PubMed 31218354 ↗
  • Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Nicolau JC, Parkhomenko A, Lopez-Sendon J, Dellborg M, Diaz R, Van de Werf F, Corbalan R, Goudev A, Jensen EC, Johanson P, Braunwald E, Sabatine MS. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. J Am Heart Assoc. 2018 Nov 20;7(22):e009260. doi: 10.1161/JAHA.118.009260. PubMed 30571502 ↗
  • Bansilal S, Bonaca MP, Cornel JH, Storey RF, Bhatt DL, Steg PG, Im K, Murphy SA, Angiolillo DJ, Kiss RG, Parkhomenko AN, Lopez-Sendon J, Isaza D, Goudev A, Kontny F, Held P, Jensen EC, Braunwald E, Sabatine MS, Oude Ophuis AJ. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. J Am Coll Cardiol. 2018 Feb 6;71(5):489-496. doi: 10.1016/j.jacc.2017.11.050. PubMed 29406853 ↗
  • Cavallari I, Morrow DA, Creager MA, Olin J, Bhatt DL, Steg PG, Storey RF, Cohen M, Scirica BS, Piazza G, Goodrich EL, Braunwald E, Sabatine MS, Bonaca MP. Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation. 2018 Feb 13;137(7):684-692. doi: 10.1161/CIRCULATIONAHA.117.031062. Epub 2017 Oct 30. PubMed 29084737 ↗
  • Bonaca MP, Storey RF, Theroux P, Steg PG, Bhatt DL, Cohen MC, Im K, Murphy SA, Magnani G, Ophuis TO, Rudah M, Parkhomenko A, Isaza D, Kamensky G, Goudev A, Montalescot G, Jensen EC, Johanson P, Braunwald E, Sabatine MS. Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol. 2017 Sep 12;70(11):1368-1375. doi: 10.1016/j.jacc.2017.07.768. PubMed 28882235 ↗
  • Magnuson EA, Li H, Wang K, Vilain K, Shafiq A, Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Braunwald E, Sabatine MS, Cohen DJ; PEGASUS-TIMI 54 Trial Investigators. Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol. 2017 Aug 1;70(5):527-538. doi: 10.1016/j.jacc.2017.05.063. PubMed 28750695 ↗
  • Thomas MR, Angiolillo DJ, Bonaca MP, Ajjan RA, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Sabatine MS, Storey RF. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thromb Haemost. 2017 May 3;117(5):940-947. doi: 10.1160/TH16-09-0703. Epub 2017 Mar 16. PubMed 28300867 ↗
  • Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, Goodrich E, Mauri L, Ophuis TO, Ruda M, Spinar J, Seung KB, Hu D, Dalby AJ, Jensen E, Held P, Morrow DA, Braunwald E, Sabatine MS. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation. 2016 Sep 20;134(12):861-71. doi: 10.1161/CIRCULATIONAHA.116.024637. Epub 2016 Aug 30. PubMed 27576775 ↗
  • Bonaca MP, Bhatt DL, Oude Ophuis T, Steg PG, Storey R, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Theroux P, Hamm C, Spinar J, Kiss RG, Dalby AJ, Medina FA, Kontny F, Aylward PE, Jensen EC, Held P, Braunwald E, Sabatine MS. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. JAMA Cardiol. 2016 Jul 1;1(4):425-32. doi: 10.1001/jamacardio.2016.1017. PubMed 27438319 ↗
  • Held P, Himmelmann A, Ditmarsch M. Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program. Future Cardiol. 2016 Jul;12(4):405-18. doi: 10.2217/fca-2016-0028. Epub 2016 May 10. PubMed 27160944 ↗
  • Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, Lopez-Sendon J, Dellborg M, Dalby A, Spinar J, Aylward P, Corbalan R, Abola MTB, Jensen EC, Held P, Braunwald E, Sabatine MS. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016 Jun 14;67(23):2719-2728. doi: 10.1016/j.jacc.2016.03.524. Epub 2016 Apr 1. PubMed 27046162 ↗
  • Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E, Sabatine MS, Steg PG. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016 Jun 14;67(23):2732-2740. doi: 10.1016/j.jacc.2016.03.529. Epub 2016 Apr 1. PubMed 27046160 ↗
  • Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Oude Ophuis T, Budaj A, Goto S, Lopez-Sendon J, Diaz R, Dalby A, Van de Werf F, Ardissino D, Montalescot G, Aylward P, Magnani G, Jensen EC, Held P, Braunwald E, Sabatine MS. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016 Apr 7;37(14):1133-42. doi: 10.1093/eurheartj/ehv531. Epub 2015 Oct 21. PubMed 26491109 ↗
  • Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Jensen EC, Sabatine MS. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J. 2014 Apr;167(4):437-444.e5. doi: 10.1016/j.ahj.2013.12.020. Epub 2014 Jan 6. PubMed 24655690 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2010
First posted
Oct 21, 2010
Start
Oct 2010
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Dec 9, 2015
Last update
Jan 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01225562
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 21, 2010
Start date
Oct 2010
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Dec 9, 2015
Last update
Jan 25, 2016

Study contacts

Eugene Braunwald, MD
study chair · The TIMI Study Group
Marc Sabatine, MD, MPh
principal investigator · The TIMI Study Group
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion